ILMN•prnewswire•
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
Summary
The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 20, 2026 by prnewswire